Gibco Recombinant AOF Insulin

High-purity, animal origin–free insulin designed to deliver consistent performance in serum-free and chemically defined media. Gibco Recombinant Human (rHu) Insulin AOF helps you achieve reliable, scalable biologics production with confidence. Manufactured to stringent quality standards and validated through years of internal development, it supports consistent outcomes from early research through scale-up.

Gibco rHu Insulin AOF is a recombinant insulin supplement developed for advanced cell culture and bioproduction applications. Produced using recombinant DNA technology and a fully animal origin–free (AOF) process, it helps minimize contamination risk while supporting consistent cell growth and productivity.

Gibco AOF Insulin enables dependable performance in serum-free and chemically defined media across a wide range of biologics workflows.

• Consistent performance across cell systems: Supports robust growth and productivity in CHO, HEK293, Hybridoma, VERO, and stem cell cultures.   
       
•  Animal origin–free and GMP-aligned: Manufactured without animal-derived components to reduce contamination risk and support global regulatory expectations.
  
  
• Reproducible results you can trust: Engineered for lot-to-lot consistency, helping ensure reliable outcomes across development and production runs.
  
  
• Scalable for biomanufacturing: Supports seamless scale-up with globally verified supply and adherence to GMP principles.
  
  
• Flexible to your process needs: Available in customizable volumes and packaging formats to integrate easily into your workflow.

Gibco rHu Insulin AOF is ideal for a wide range of applications, including:

• Monoclonal antibody production (CHO, Hybridoma, NS0, myeloma)
• Viral vector manufacturing (HEK293, VERO)
• Recombinant protein expression
• Vaccine development
• Stem cell expansion and maintenance

As a critical growth factor, insulin regulates glucose uptake and cellular metabolism—key drivers of cell viability, proliferation, and protein expression.

In serum-free and chemically defined systems, recombinant human insulin helps maintain consistent culture conditions while reducing variability associated with animal-derived components.

Gibco rHu Insulin AOF is manufactured using advanced recombinant DNA technology under rigorous quality and testing standards trusted by scientists worldwide. Validated over years of internal media development.

Key quality attributes:

• USP/EP grade compliance
• Animal origin–free (AOF) manufacturing
• GMP-aligned production processes
• Documented traceability
• Reliable global supply chain 

From process development to large-scale production, Gibco rHu Insulin AOF supports consistent performance and dependable supply.

Its scalable production formats and global availability help reduce risk and ensure continuity across your entire bioprocess.

Bring Gibco-validated performance into your bioprocess. Enhance consistency, reduce variability, and simplify regulatory alignment with high-quality recombinant human insulin.